Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.

Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty P, Carranza-Salazar DE, Carreño JM, Carranza C, Juárez E, Carreto-Binaghi LE, Ramírez-Martínez L, Paz-De la Rosa G, Vigueras-Moreno R, Ortiz-Stern A, López-Vidal Y, Macías AE, Torres-Flores J, Rojas-Martínez O, Suárez-Martínez A, Peralta-Sánchez G, Kawabata H, González-Domínguez I, Martínez-Guevara JL, Sun W, Sarfati-Mizrahi D, Soto-Priante E, Chagoya-Cortés HE, López-Macías C, Castro-Peralta F, Palese P, García-Sastre A, Krammer F, Lozano-Dubernard B

Open source

DOI: 10.1101/2022.02.08.22270676
Published: 2022 Feb 9
Container: medRxiv : the preprint server for health sciences
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 41/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
cautionPublication version: Identified as a preprint; peer review and later versions may change the record. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1101/2022.02.08.22270676,
  title = {Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.},
  author = {Ponce-de-León S and Torres M and Soto-Ramírez LE and Calva JJ and Santillán-Doherty P and Carranza-Salazar DE and Carreño JM and Carranza C and Juárez E and Carreto-Binaghi LE and Ramírez-Martínez L and Paz-De la Rosa G and Vigueras-Moreno R and Ortiz-Stern A and López-Vidal Y and Macías AE and Torres-Flores J and Rojas-Martínez O and Suárez-Martínez A and Peralta-Sánchez G and Kawabata H and González-Domínguez I and Martínez-Guevara JL and Sun W and Sarfati-Mizrahi D and Soto-Priante E and Chagoya-Cortés HE and López-Macías C and Castro-Peralta F and Palese P and García-Sastre A and Krammer F and Lozano-Dubernard B},
  year = {2022},
  journal = {medRxiv : the preprint server for health sciences},
  doi = {10.1101/2022.02.08.22270676},
  url = {https://doi.org/10.1101/2022.02.08.22270676}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
AU  - Ponce-de-León S
AU  - Torres M
AU  - Soto-Ramírez LE
AU  - Calva JJ
AU  - Santillán-Doherty P
AU  - Carranza-Salazar DE
AU  - Carreño JM
AU  - Carranza C
AU  - Juárez E
AU  - Carreto-Binaghi LE
AU  - Ramírez-Martínez L
AU  - Paz-De la Rosa G
AU  - Vigueras-Moreno R
AU  - Ortiz-Stern A
AU  - López-Vidal Y
AU  - Macías AE
AU  - Torres-Flores J
AU  - Rojas-Martínez O
AU  - Suárez-Martínez A
AU  - Peralta-Sánchez G
AU  - Kawabata H
AU  - González-Domínguez I
AU  - Martínez-Guevara JL
AU  - Sun W
AU  - Sarfati-Mizrahi D
AU  - Soto-Priante E
AU  - Chagoya-Cortés HE
AU  - López-Macías C
AU  - Castro-Peralta F
AU  - Palese P
AU  - García-Sastre A
AU  - Krammer F
AU  - Lozano-Dubernard B
PY  - 2022
JO  - medRxiv : the preprint server for health sciences
DO  - 10.1101/2022.02.08.22270676
UR  - https://doi.org/10.1101/2022.02.08.22270676
ER  -

APA

S, P., M, T., LE, S., JJ, C., P, S., DE, C., JM, C., C, C., E, J., LE, C., L, R., G, P. L. R., R, V., A, O., Y, L., AE, M., J, T., O, R., A, S., G, P., H, K., I, G., JL, M., W, S., D, S., E, S., HE, C., C, L., F, C., P, P., A, G., F, K., & B, L. (2022). Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.. medRxiv : the preprint server for health sciences. https://doi.org/10.1101/2022.02.08.22270676

Source records

pubmed · retrieved 2026-09-27T08:11:59.941Z